Recall StatusOpen, Classified
Date Initiated2021-10-13
Product Quantity1072 devices
Reason for Recall
Under certain circumstances, there can be a difference between the planned and delivered dose of the two ovoid channels.
Firm Action
An Urgent Important Field Safety Notification letter (FAC-NU-0007) was issued to consignees to notify of the issue, clinical impact and recommend the following:
1) Recommended User Action in the unique scenario, which is only applicable for the Venezia" applicator: Avoid use of the combination of the two Venezia" applicator Anchor Points O1-Center and O2-Center by disabling one of them in the Applicator Library Manager.
2)Recommended User Action in the exceptional situation that may also occur for other Applicator Models: Avoid incorrect placement of the Anchor Points, especially exchanging left / right anchor point positions.
3) Recommended User Actions for both scenarios:
Until an updated version of Oncentra Brachy is available, it is strongly advised:
" To use additional Anchor Points during applicator modelling. This will further reduce the chance of
mirroring the Applicator Model.
" To cross-check the source dwell position information from the Case Explorer to be in accordance
with the source dwell positions in the image views.
" Use the Triangles option for the applicator skin visualization in the 3D view, and review whether the
Applicator Model has a correct shading display.
" Perform proper Quality Assurance for all treatment plans before treatment delivery.
Consignees are required to acknowledge receipt of the notification to Elekta within 30 days.
Root Cause
Software design
Distribution Pattern
Distribution throughout USA
OUS distribution including:Algeria, Argentina, Australia, Austria Bahamas, Bangladesh, Belarus, Belgium, Bolivia, Botswana, Brazil Brunei, Bulgaria, Canada, Chile, China, Colombia, Croatia, Cyprus, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran (Islamic Republic of), Ireland, Israel, Italy, Japan, Jordan, Kazakhstan, Kenya, Korea, Republic of, Kosovo, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Netherlands, New Zealand, Norway, Pakistan, Peru, Philippines, Poland, Portugal, Republic of Serbia, Romania, Russian Federation, Saudi Arabia, Senegal, Singapore, Slovakia, South Africa, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, Tunisia, Turkey, Ukraine, United Arab Emirates, United Kingdom, Uzbekistan, Venezuela, Vietnam
Official Source
View FDA Recall →Source: FDA Enforcement Report / Recall database. Always confirm against the official FDA record.